Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Core Insights - Alvotech has entered into supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand, enhancing its global market strategy ahead of regulatory approvals [1][2] Group 1: Agreements and Responsibilities - The agreement in Canada includes one biosimilar candidate in ophthalmology, supplied as a prefilled syringe for intravitreal injection [2] - In Australia and New Zealand, the agreement covers three biosimilar candidates across immunology and gastroenterology in various formulations [2] - Sandoz will handle regulatory submissions, commercialization, and distribution, while Alvotech will manage development, global clinical activities, and manufacturing, supplying finished products to Sandoz under exclusive arrangements [3] Group 2: Strategic Goals and Market Presence - The collaboration aims to enhance patient access to biologic medicines in Canada, Australia, and New Zealand, with Sandoz committed to providing sustainable and affordable solutions [4] - Alvotech's strategy focuses on securing commercial pathways for its biosimilars portfolio globally, leveraging its integrated development and manufacturing platform [2][4] - Alvotech has five biosimilars already approved and marketed in various global markets, with a pipeline of nine disclosed biosimilar candidates targeting multiple therapeutic areas [5]